In this study, we characterized a muscarinic acetylcholine receptor (mAChR) potentiator, LY2119620 (3-amino-5-chloro-Ncyclopropyl-4-methyl-6-[2-(4-methylpiperazin-1-yl)-2-oxoethoxy] thieno [2,3-b]pyridine-2-carboxamide) as a novel probe of the human M 2 and M 4 allosteric binding sites. Since the discovery of allosteric binding sites on G protein-coupled receptors, compounds targeting these novel sites have been starting to emerge. For example, LY2033298 (3-amino-5-chloro-6-methoxy-4-methylthieno(2,3-b)pyridine-2-carboxylic acid cyclopropylamid) and a derivative of this chemical scaffold, VU152100 (3-amino-N-(4-methoxybenzyl)-4,6-dimethylthieno[2,3-b]pyridine carboxamide), bind to the human M 4 mAChR allosteric pocket. In the current study, we characterized LY2119620, a compound similar in structure to LY2033298 and binds to the same allosteric site on the human M 4 mAChRs. However, LY2119620 also binds to an allosteric site on the human M 2 subtype. [ 
Introduction
Acetylcholine activates two families of receptors: the nicotinic ligand-gated ion channel receptors (nAChRs) and the G protein-coupled muscarinic receptors (mAChRs), classified initially based on their differential activation by nicotine (Lindstrom, 1997) and muscarine (Wess, 1996) , respectively. The wide distribution of mAChRs in the central nervous system (CNS) and periphery support their involvement in physiologic processes such as arousal, cognition, pain, exocrine gland secretion, smooth muscle, and vascular contraction (Wess et al., 2003) . Muscarinic acetylcholine receptors have long been viewed as viable targets for developing therapeutic agents to treat Alzheimer's disease and other CNS disorders. The muscarinic agonist xanomeline, for example, was developed to treat Alzheimer's disease (Bodick et al., 1994) , but it was also found to induce improvements in positive, negative, and cognitive symptoms associated with schizophrenia (Shekhar et al., 2008) . However, the lack of selectivity of xanomeline led to peripheral side effects that prohibited it from advancing in the clinic. Because of the highly conserved sequence within the acetylcholine binding domain (Heinrich et al., 2009) , targeting the orthosteric site for small molecule development resulted in a number of muscarinic agonist compounds with poor selectivity.
However, the discovery of allosteric sites on G proteincoupled receptors (GPCRs) is allowing more selective small molecule modulators to emerge, offering a unique approach to treating CNS diseases (Christopoulos, 2002; May et al., 2007) . Allosteric modulators bind to novel sites that are distinct from the natural transmitter orthosteric binding site. Positive dx.doi.org/10.1124/mol.114.091785. s This article has supplemental material available at molpharm. aspetjournals.org. allosteric modulators enhance the affinity and/or efficacy of the endogenous ligand and have a number of therapeutic advantages compared with direct-acting agonists such as xanomeline. Besides the observation of improved receptor selectivity, positive allosteric modulators offer physiologically relevant spatial and temporal signaling that may limit undesirable side effects compared with direct-acting agonists that can lead to desensitization and long-term changes in receptor densities (Christopoulos, 2002) .
ABBREVIATIONS: [
Several in vitro pharmacologic methods can be used to assess allosteric binding and functional signaling modulation. Typically, muscarinic allosteric agents have been identified by the effect they induce on radioligand competition experiments at the orthosteric site (Birdsall et al., 1997 3-b] pyridine-2-carboxamide) that allows direct labeling of the muscarinic allosteric site. In addition, we discuss the possibility of being able to discern muscarinic allosteric binding sites in native tissue. Our data support the hypothesis that allosteric selectivity between M 2 and M 4 mAChR subtypes with LY2119620 is a result of differences in cooperativity and not affinity of the orthosteric agonist, similar to what has been previously described for thiochrome (Lazareno et al., 2004) and LY2033298 (3-amino-5-chloro-6-methoxy-4-methyl-thieno(2,3-b) pyridine-2-carboxylic acid cyclopropylamide) (Leach et al., 2010) at the M 4 mAChR.
Materials and Methods
Chinese hamster ovary cell lines stably expressing human M 1 (B max NMS 5 4.4 pmol/mg membrane), M 2 (B max NMS 5 11.0 pmol/mg membrane), M 3 (B max NMS 5 7.64 pmol/mg membrane), M 4 (B max NMS 5 3.3 pmol/mg membrane), or M 5 (B max NMS 5 4.2 pmol/mg membrane) were purchased from PerkinElmer (Waltham, MA). Chemicals and ligands were purchased from the following sources: oxotremorine-M, VU152100 (3-amino-N-(4-methoxybenzyl)-4,6-dim ethylthieno[2,3-b] pyridine carboxamide), and VU10010 (3-amino-N-[(4-chlorophenyl) methyl]-4,6-dimethylthieno[2, 3-b] pyridine-2-carboxamide) from Tocris (Bristol, UK); acetylcholine, WIN 62, ]NMS binding assays were performed in HEPES buffer [20 mM HEPES, 100 mM sodium chloride (NaCl), 10 mM magnesium chloride (MgCl 2 ), pH 7.4] as described previously (Chan et al., 2008) with the following modifications. Briefly, frozen membrane preparations were thawed and resuspended in assay buffer, and approximately 25 mg protein was added to each well and incubated with [ 3 H]NMS for 2 hours at room temperature in a total volume of 200 ml in polypropylene 96-deep well plates. Nonspecific binding was determined using 10 mM atropine. Membranes were collected by rapid filtration using a Tomtec cell harvester (Tomtec, Inc., Hamden, CT) through GF/A filters that had been presoaked in 0.3% polyethyleneimine. The filters were washed with 5 ml of ice-cold 50 mM Tris buffer (pH 7.4) and air-dried overnight. The dried filters were treated with MeltiLex A melt-on scintillator sheets, and the radioactivity retained on the filters was counted using a Wallac 1205 Betaplate scintillation counter (PerkinElmer 3 H]NMS, various concentrations of orthosteric agonists were used to displace the radioligand but in the presence of 10.0, 1.0, 0.1, or 0 mM LY2119620. The dissociation kinetic binding assays were performed using a reverse-time protocol. For these experiments, P1 membrane preparations of a Chinese hamster ovary cell line stably expressing either the human M 2 or M 4 muscarinic mAChR were used. Membranes were added to approximately 1.0 nM [ 3 H]NMS in the presence or absence of LY2119620 and allowed to equilibrate for 2 hours at room temperature. Once equilibrated, 100 mM oxotremorine-M was added in a time-staggered approach to allow 1-to 60-minute time point collection. In the statistical analyses, K i values were determined from the Cheng-Prusoff relationship:
where IC 50 is determined from a four-parameter fit of displacement curves, [ligand] 3 H]LY2119620 at approximately the K d concentration of the receptor, and varying concentrations (0.1 nM-10 mM) of allosteric ligands gallamine, VU152100, VU10010, WIN 62,577, LY2033298, and LY2119620. Incubations were carried out for 1 hour at room temperature. All reactions were stopped by rapid filtration on a Tomtec 96-well cell harvester. Nonspecific binding was determined using 10 mM LY2033298. Radioactivity retained on the filtermats was counted on a Wallac 1205 Betaplate. In the statistical analyses, the specific binding versus time data were fit to a one-site specific binding model using GraphPad Prism 6.7 and the B max and K d for the allosteric molecule was calculated for each orthosteric ligand. K i values were determined using the Cheng-Prusoff relationship for [
. Male cynomolgus monkey brains were supplied from Covance (Greenfield, IN). Brains were rapidly removed, placed in ice-cold phosphate-buffered saline (PBS) for 5 minutes, frozen on dry ice, and then stored at 280°C. The brains were mounted onto chucks and sectioned at 12 mm using a cryostat (Zeiss, Thornwood, NY). Sagittal sections were thawmounted onto gelatin-coated slides and stored at 280°C until being assayed. Sections were initially preincubated for 10 minutes in PBS at room temperature. The sections were then placed into polypropylene containers with approximately 5.0 nM [ plate was read in Fuji BAS-5000 and analyzed using MCID Software (Cambridge, UK).
Results
Previous studies have revealed that the mAChRs possess at least one allosteric site located extracellularly to the orthosteric site (Wess, 2005) . This pocket is referred to as the "common" allosteric site because prototypical modulators, such as gallamine, alcuronium, and C 7 /3-phth, interact with all five mAChR subtypes, albeit with different degrees of affinity or selectivity . In this study, we describe the identification of a novel positive allosteric modulator, LY2119620, for common allosteric site on the human M 2 and M 4 mAChR. For comparison's sake, we also evaluated other muscarinic allosteric compounds, including LY2033298, VU10010, VU152100, gallamine, and WIN 62,577 (Fig. 1) .
Binding Analysis of LY2119620 2) . The competition for atropine and LY2119620 for M 1 -M 5 mAChRs is summarized in Table 1 . To address whether LY2119620 interacts with the human mAChRs in an allosteric manner, radioligand dissociation experiments were performed to determine whether coincubating LY2119620 with the nonselective muscarinic agonist, oxotremorine-M, changed the off-rate (t 1/2 ) of [ 3 H]NMS because altered dissociation rates can be indicative of an allosteric interaction. Figure 3 illustrates the dissociation of [ 3 H]NMS by oxotremorine-M in the presence of various concentrations of LY2119620 for both the human M 2 and M 4 mAChRs. The offrate of [ 3 H]NMS in the presence of oxotremorine-M was significantly reduced for both M 2 (Fig. 3A) and M 4 (Fig. 3B ) by LY2119620 and could be fitted to a one-phase exponential decay model. The t 1/2 for M 2 mAChR alone was 2.5 minutes and in the presence 10 mM LY2119620 doubled to 5.8 minutes. The t 1/2 of the radioligand at M 2 mAChR decreased in a concentration-dependent manner as more LY2119620 was added. The t 1/2 at 20 mM was 15.2 minutes and at 40 mM increased to 51.8 minutes. The t 1/2 for the dissociation of [ 3 H]NMS by oxotremorine-M for the M 4 mAChR was 11.5 minute but, in the presence 10 mM LY2119620, nearly quadrupled to 44.6 minutes. Like the M 2 mAChR, the t 1/2 of [ 3 H]NMS at the M 4 decreases in a concentration-dependent manner. The t 1/2 at 5 mM was 18.7 minutes and at 20 mM increased to 116.7 minutes. Clearly, the dissociation kinetic studies indicated that LY2119620 binds allosterically to the human M 2 and M 4 mAChRs and was positively cooperative with orthosteric ligand binding. To test an alternative approach to determine whether LY2119620 can be positively cooperative with orthosteric agonist binding, we measured the influence of LY2119620 on the ability of acetylcholine or oxotremorine-M to displace [ 3 H]NMS (Fig. 4) . LY2119620 was positively cooperative in its enhancement of orthosteric agonist competition for [
3 H]NMS binding as shown by a leftward shift in the binding curve for both agonists. LY2119620 was significantly more cooperative at the M 4 mAChR compared with its cooperativity at M 2 for both acetylcholine and oxotremorine-M. Application of an allosteric ternary complex model (Christopoulos and Kenakin, 2002) using the equation built in to the GraphPad Prism program yielded the logarithm of cooperativity factor (loga) for LY2119620 in the presence of acetylcholine, which was 0.7 and 1.9 for M 2 and M 4 , respectively. LY2119620 increased oxotremorine-M affinity at the M 2 receptor with a loga of 1.5, whereas M 4 increased by a loga of 2.3. H]LY2119620 at the human M 2 were not significantly different (P 5 0.89, n 5 3, Student's t test): 12.9 6 3.24 nM and 14.4 6 2.7 nM in the presence of 100 mM acetylcholine or oxotremorine-M, respectively. The B max value for [ 3 H]LY2119620 binding to the human M 2 was 160 6 34 fmol/mg protein in the presence of 100 mM acetylcholine. However, in the presence of 100 oxotremorine-M, the number of binding sites increased 17-fold (2700 6 383 fmol/mg of protein). The M 4 mAChR was similar to M 2 in that the K d values for 100 mM acetylcholine and oxotremorine-M were not significantly different (P 5 0.57, n 5 3, Student's t test): 2.54 6 0.39 nM and 2.73 6 0.08 nM, respectively. The B max values for the M 4 mAChR were significantly higher in the presence of 100 mM oxotremorine-M (1110 6 157 fmol/mg of protein) compared with acetylcholine (468 6 54 fmol/mg of protein) (P . 0.02, n 5 3, Student's t test). The concentrations of acetylcholine and oxotremorine-M were titered from 0-1000 mM, and 100 mM yielded a maximal response for both M 2 and M 4 mAChRs (data not shown). Displacement studies were conducted with [ 3 H]LY2119620 at the human M 2 or M 4 mAChRs to elucidate whether this compound bound to a unique allosteric site on these receptors or to previously published sites using key allosteric tool compounds. and M 4 with a K i of 2.14 6 0.28 nM (Fig. 5) . We also investigated whether LY2119620 bound to either the putative strychnine or staurosporine allosteric sites by displacing (Table 3 ). Other M 4 allosteric modulators similar to LY2033298, VU152100, and VU10010 were also able to displace [
3 H]LY2119620 from the human M 4 mAChR but not M 2 . This result was expected based on previous work that has demonstrated that these compounds are selective for the M 4 receptor Shirey et al., 2008) Autoradiographic Fig. 1) . Because LY2119620 has relatively low affinity for rodent mAChRs similar to LY2033298, we relied on the distribution of the M 4 allosteric binding sites in the cynomolgus monkey to give us insight into the distribution in higher species. Cynomolgus monkeys have nearly identical M 2 and M 4 mAChRs sequences as humans. In general, [ 3 H]LY2119620 binding in monkeys was broadly distributed in the cortex and devoid in the cerebellum (Fig. 6) . Some of the highest levels of binding with [
were observed in the caudate-putamen and the superficial (I-III) laminae of the cerebral cortex (Fig. 6A) . [ 3 H]LY2119620 binding was almost completely eliminated by the presence of 10 mM LY2033298 (Fig. 6B) . Therefore, the amount of radioligand binding remaining in Fig. 6B represents nonspecific binding.
Discussion
The five subtypes of mAChRs are members of the superfamily of G protein-coupled receptors (Caulfield and Birdsall, 1998) and are now known to have allosteric binding sites that provide significant modulation of functional signaling (Christopoulos et al., 1998; Christopoulos, 2002; Christopoulos and Kenakin, 2002) . In the present study, we showed that the allosteric modulator LY2119620 exerts its modulator effects through a common site on the M 4 mAChR, similar to LY2033298 (Chan et al., 2008) , which has been extensively studied using mutagenesis (Leach et al., 2010) . In agreement with LY2033298, our findings clearly indicate that LY2119620 is a novel allosteric compound that does not interact with the orthosteric site, similar to the properties of known allosteric compounds such as staurosporine (Lazareno et al., 2000) or strychnine (Ellis et al., 1991) . To investigate whether LY2119620 bound to mAChRs in a bitopic manner (a ligand engaging both the orthosteric and allosteric sites at the same time), we used [ (Fig. 2) . A radiolabeled allosteric modulator of mAChRs was first described for the M 2 mAChR using [
3 H]dimethyl-W84 (N,N9-bis [3-(1,3-dihydro-5-methyl-1,3-dioxo-2H-isoindol-2-yl) propyl]-N,N,N9,N9-tetramethyl-1,6-hexanediamminium dibromide) (Tränkle et al., 1998) . Prototype muscarinic allosteric agents alcuronium and gallamine displaced in a concentration-dependent manner the high-affinity site of [ 3 H]dimethyl-W84 binding, These data led Tränkle and colleagues (1998) to conclude that this radioligand bound to the "common" allosteric site on M 2 . compound, LY2033298, at the mouse M 4 mAChR (Suratman et al., 2011) . In that study, it was speculated that the probe dependence was due to different cooperativities between modulator and orthosteric ligands because LY2033298 had similar affinities for both human and mouse M 4 allosteric sites. The positive cooperativity between acetylcholine and LY2033298 was most evident at the human M 4 and was lower at the human M 2 and essentially neutral at the other mAChR subtypes (Chan et al., 2008) . We see similar cooperativity differences between M 2 and M 4 with acetylcholine or oxotremorine-M using [ 3 H]NMS binding (Fig. 4) . Therefore, one could speculate that the difference in the B max values between orthosteric agonists with [ 3 H]LY2119620 was due to a similar mechanism. That is, increased modulator binding was directly proportionate to the number of active state receptors since it is well known that GPCRs exist in two states, active (RG) and inactive (R). Although the exact mechanism remains unclear, a common interpretation is that this somehow reflects the coupling of the GPCR to the G protein(s) to promote the active state (Christopoulos and ElFakahany, 1999) . Not yet tested was whether the functional positive allosteric modulation by either LY2033298 or LY2119620 can be driven by increasing the cooperativity between orthosteric ligand and G protein binding, thus increasing the number of G protein-bound mAChRs, thereby increasing the functional output of the signaling being measured. This interaction could be inferred because functional [
35 S]GTPgS binding was positively modulated by LY2119620 (Croy et al., 2014) . Furthermore, emerging crystal structure studies with allosteric compounds might shed some light on probe dependence. Recently, the M 2 mAChR was crystalized in the active state with iperoxo docked in the orthosteric binding pocket in the presence of LY2119620 (Kruse et al., 2013) . The M 2 crystal structure revealed that LY2119620 induces additional, albeit subtle, structural changes compared with those seen with just the orthosteric agonist.
Like its predecessor LY2033298, LY2119620 is also subject to species variability. In the initial characterization of LY2033298, it was noted that this compound had reduced in vitro potency as a modulator in the rat compared with the human M 4 mAChR (Chan et al., 2008) and later for the mouse (Suratman et al., 2011) . However, the affinity for LY2033298 across species has been shown to be very similar (Leach et al., 2010; Suratman et al., 2011; Valant et al., 2012) in several assay formats. In contrast, any attempt to get [ 3 H]LY2119620 to bind to either recombinantly expressed rodent muscarinic or native tissue in the presence of any orthosteric agonist was not successful. However, it should be pointed out that the concentrations of radioligand used were limited as a result of reagent costs as well as increasing nonspecific binding at higher concentrations. These direct-labeling experiments with a radiolabeled allosteric probe contradict previous reports using various functional assays that these allosteric modulators have similar affinity across species (Leach et al., 2010; Suratman et al., 2011; Valant et al., 2012) . In addition, we used [ 3 H]LY2119620 to probe the distribution of these allosteric sites in the brain. We used nonhuman primates as the gene sequences between them and humans are nearly identical. We found the distribution of [ 3 H]LY2119620 to be similar to the distribution of M 2 and M 4 mAChRs using [ 3-b] [1,4]benzodiazepine-11-carboxamide), a selective M 2 and M 4 antagonist of the muscarinic acetylcholine receptors (Quirion et al., 1993) . [ 3 H]AF-DX 384 binds preferentially to the striatum, cortex, thalamus, and cerebellum.
In summary, we have identified LY2119620 as an allosteric modulator of the human M 2 and M 4 mAChRs. Our data 1.03 6 0.0776 2.14 6 0.279 42.6 6 16.4 48.3 6 10.7 .10,000 .10,000 support the hypothesis that allosteric selectivity between M 2 and M 4 mAChR subtypes was the result of differences in cooperativity with the endogenous agonist, exemplifying probe dependence. Cooperativity governing selectivity, rather than affinity for a unique allosteric site, has been previously reported with thiochrome (Lazareno et al., 2004) and LY2033298 (Leach et al., 2010) . This supports our hypothesis that the allosteric modulators can recruit G protein coupling because the number of high-affinity binding sites labeled with [ 3 H]acetylcholine significantly increases in the presence of thiochrome, and LY2119620 increased the number of highaffinity binding sites using [
3 H]oxotremorine-M (Croy et al., 2014) . Likewise, we report in this study that the affinity of [ 3 H]LY2119620 was similar in the orthosteric agonists, but the total number of binding sites was significantly different between agonists. In conclusion, not all orthosteric agonists recruit high-affinity binding sites to the same extent, and allosteric binding governs G protein recruitment cooperatively with orthosteric agonist binding.
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